A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
A phase 2 trial of Imlunestrant and Tamoxifen in HR-positive / HER2-negative breast cancer, run by Eli Lilly and Company, now recruiting.
Overview
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer is a phase 2 interventional study registered as NCT07287098 by Eli Lilly and Company, with 600 participants planned, started 2026-05-13 and due to reach its primary completion in 2029-01. Interventions recorded: Imlunestrant, Goserelin and Tamoxifen 20 mg.
Similar pages
not linked directly; found by shared links- TrialA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Shares Imlunestrant, Tamoxifen, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Tamoxifen, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Eli Lilly (incl. Loxo), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Tamoxifen, Eli Lilly (incl. Loxo) and the tag pipeline.
- TreatmentTersolisib
Shares Eli Lilly (incl. Loxo), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Eli Lilly (incl. Loxo) and the tag pipeline.